Pfizer (NYSE:PFE) has reportedly succeeded in getting a U.K. court to invalidate two of GSK’s (NYSE:GSK) patents for its RSV ...

Pfizer on Monday won a bid in a London court to invalidate two of GSK's patents relating to a respiratory syncytial virus ...

If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...

Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

Emma Walmsley, CEO of GSK, is nearly eight years into her effort to return the British pharma company to growth, and her work ...

AREXVY is approved for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older, as well as individuals 50 ...

GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced that Arexvy (MAL24086007ARZ) has been approved in Malaysia for ...

Arexvy is a brand-name respiratory syncytial virus (RSV) vaccine. It’s used in some adults to help prevent lung disease from RSV. Arexvy should not be used during pregnancy and breastfeeding.

Arexvy has been approved in Malaysia for RSV (respiratory syncytial virus), for older adults aged 60 and above. The vaccine ...

The revision comes as the analyst anticipates GlaxoSmithKline's third-quarter sales and profits to likely fall short of consensus estimates, primarily due to weaker than expected performance of US ...